January 13, 2021 Clinical Research/Diagn. Life Science Tools

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate... Read more

January 13, 2021 Clinical Research/Diagn. Life Science Tools

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate... Read more

January 11, 2021 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 Licensing, IP, and Legal M&A, Partnerships Product Launch

Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling

SAN DIEGO–(BUSINESS WIRE)–With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company’s commitment to develop standardized, globally distributable tools for precision oncology. Speaking today at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Illumina... Read more

January 7, 2021 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics

Adds to MilliporeSigma’s lipid manufacturing expertise, providing an integrated offering across mRNA value chain AmpTec’s differentiated polymerase chain reaction (PCR)-based technology has shown to have advantages over other technologies for mRNA manufacturing Diagnostics business focused on producing customized long RNAs and DNAs for in vitro diagnostics, complements existing MilliporeSigma portfolio Burlington, Massachusetts, January 7, 2020 — MilliporeSigma today... Read more

January 4, 2021 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal Mass Spectrometry

Bruker Introduces MBT Sepsityper® Kit US IVD for Rapid and Affordable Identification of over 400 Microorganisms from Positive Blood Cultures

MBT Sepsityper Kit US IVD enables rapid, specific detection of many cases of bacteremia-induced sepsis to assist infectious disease specialists in potentially life-saving decisions Used for MALDI Biotyper® (MBT) identification directly from Positive Blood Cultures (PBC) with short time-to-result (TTR) of less than 30 minutes US FDA clearance received in late December for diagnostic use... Read more

December 28, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

Quanterix Receives FDA Emergency Use Authorization for Semi-quantitative Antibody Test

Infectious Disease Technology Antibody test available on Simoa HD-X Analyzer® detects and quantitates IgG antibodies to SARS-CoV-2 in serum or EDTA plasma   BILLERICA, Mass., December 28, 2020 – Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use... Read more

December 21, 2020 Clinical Research/Diagn. Life Science Tools Product Launch

Release of Fully-Automatic PCR Testing System for Clinics Contributes to Japan’s COVID-19 Testing Capabilities

Shimadzu Corporation has released the AutoAmp Genetic Analyzer (“AutoAmp”) for sale in Japan, enabling clinics to perform fully-automatic PCR testing. With the AutoAmp, classified as a Class I medical device, PCR testing involves simply setting the biological samples, dispensing tips, reagent vials, and reaction vessels in place. This instrument can also be used to detect... Read more

December 16, 2020 Clinical Research/Diagn. Lab Top-10 Liq. Handling & Robotics Product Launch

EUROIMMUN Launches Novel ELISA for Detection of SARS-CoV-2 Antigen in Acutely Infected Patients

Automatable and reliable COVID-19 test rounds out Company’s menu of offerings for acute diagnostics of the virus WALTHAM, Mass. – December 16, 2020 – EUROIMMUN, a PerkinElmer, Inc. Company, today announced the launch of the CE marked SARS-CoV-2 Antigen ELISA for specific determination of the SARS-CoV-2 protein. The assay adds to the Company’s broad product... Read more

December 15, 2020 Clinical Research/Diagn. Life Science Tools PR/Corporate

Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors

December 15, 2020 SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K. Stankovic, MD, PhD, MSPH, to the company’s Board of Directors. Dr. Stankovic is a seasoned leader with more than 30 years of research... Read more